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The relevance of environmental triggers in Crohn's disease remains poorly explored, 
despite the well- known association between industrialization and disease onset/pro-
gression. We have aimed at evaluating the influence of endocrine disrupting chemi-
cals in CD patients. We performed a prospective observational study on consecutive 
patients diagnosed of CD. Serum levels of endocrine disruptors, short- chain fatty 
acids, tryptophan and cytokines were measured. Bacterial- DNA and serum endotoxin 
levels were also evaluated. Gene expression of ER- α, ER- β and GPER was measured 
in PBMCs. All patients were genotyped for NOD2 and ATG16L1 polymorphisms. A 
series of 200 CD patients (140 in remission, 60 with active disease) was included in 
the study. Bisphenol A was significantly higher in patients with active disease versus 
remission and in colonic versus ileal disease. GPER was significantly increased in 
active patients and correlated with BPA levels. BPA was significantly increased in 
patients with bacterial- DNA and correlated with serum endotoxin levels, (r = 0.417; 
P = .003). Serum butyrate and tryptophan levels were significantly lower in patients 
with bacterial- DNA and an inverse relationship was present between them and BPA 
levels (r = −0.491; P = .001) (r = −0.611; P = .001). Serum BPA levels correlated 
with IL- 23 (r = 0.807; P = .001) and IL- 17A (r = 0.743; P = .001). The multivariate 
analysis revealed an independent significant contribution of BPA and bacterial- DNA 
to serum levels of IL- 23 and IL- 17A. In conclusion, bisphenol A significantly affects 
systemic inflammatory response in CD patients with gut barrier disruption and dys-
biotic microbiota secretory products in blood. These results provide evidence of an 
endocrine disruptor playing an actual pathogenic role on CD.
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1 |  BACKGROUND
Crohn's disease (CD) is a major form of inflammatory bowel 
disease with a relevant incidence worldwide.1 The genetic 
background, several environmental factors and a deregulated 
immune interaction with the gut microbiota content are in-
volved in the development and progression of this chronic 
multifactorial disease.2
The inflammatory response in CD patients shows important 
local and systemic exacerbations that characterize disease flares. 
Even during remission periods, a pathological Th17 response is 
expanded in gut tissue of CD patients, and the functional activ-
ity of epithelial cells is significantly decreased.3 Gut bacterial 
antigen translocation into blood contributes to systemic dissem-
ination of pro- inflammatory molecules such as TNF- alpha or 
IL- 6, and it constitutes an independent risk factor of flare in 
CD patients.4,5 Bacterial translocation events are facilitated by 
the microbiota dysbiotic state acquired during disease and the 
increased permeability induced by the barrier integrity loss and 
the inflammatory infiltration developed in response to microbi-
ota composition changes.6 The effect of bacterial antigen trans-
location on systemic inflammation is particularly important in 
patients bearing variant NOD2 genotypes.7
In the recent years, the role of environmental chemical 
pollutants in the pathogenesis of metabolic diseases has been 
investigated. Endocrine- disrupting chemicals (EDCs) are a 
group of pollutants able to interfere with different hormone 
actions.8 The relationship between obesity and specific EDCs 
exposure has been proven in different experimental mod-
els.9- 11 This interaction has also been described to predispose 
to chronic diseases such as type 2 diabetes,10,12,13 and non- 
alcoholic fatty liver disease (NAFLD).14,15 Moreover, the 
relationship established between EDCs and increased prev-
alence of obesity and type 2 diabetes has been supported by 
epidemiological studies.16,17
Certain EDCs, such as bisphenol A (BPA) may affect 
intestinal microbial amino acid metabolism.18 Dietary BPA 
intake is considered to influence the composition of gut mi-
crobiota.19 In fact, the microbiota of mice fed with BPA sig-
nificantly reduces its diversity of species.20 In these animals, 
BPA favors increments in Proteobacteria while Clostridia 
populations are reduced, clearly pointing towards a state 
of microbiota dysbiosis. Alterations in the abundance of 
Proteobacteria have been associated with the instability of 
gut microbiota composition which, in turn, is considered 
as a driver of intestinal inflammation.21 As gut dysbiosis in 
patients with Crohn's disease (CD) favors bacterial antigen 
translocation and an altered immune interaction with the host, 
facilitating disease flares, EDCs may constitute a trigger for 
dysbiosis- related inflammatory exacerbation in CD patients.
While both genetic predisposition and microbiota- derived 
factors have been more intensively studied in CD, the rele-
vance of metabolic associated triggers remain less explored, 
despite the known association between factors such as diet or 
hormones22 with disease onset and progression. This proof- 
of- concept study has aimed at evaluating the influence of 
serum EDCs in disease activity and phenotype, their inter-
action with dysbiosis- derived bacterial products and the sys-
temic inflammatory response in CD patients.
2 |  PATIENTS AND METHODS
2.1 | Patients and study design
Prospective observational study on consecutive patients di-
agnosed of CD and managed at the IBD Unit of Hospital 
General Universitario de Alicante. Standard clinical, endo-
scopic, histological and radiographical criteria were used to 
establish diagnosis.23 Clinical and analytical characteristics 
of patients at inclusion were recorded. Disease activity was 
determined by Crohn's disease activity index (CDAI) > 150 
and presence of clinical symptoms of relapse. The use of an-
tibiotics in the previous 4 weeks, signs of active infection and 
refusal to sign informed consent to participate in the study 
were considered as exclusion criteria. All patients were cat-
egorized by the Montreal classification. All included patients 
were provided with diaries in order to record their symptoms 
a week prior to inclusion in the study.
Peripheral blood samples were collected aseptically 
Vacutainer SST II (BD Diagnostics, Erembodegem, 
Belgium). Serum and peripheral blood mononuclear cells 
(PBMCs) were collected, aliquoted and immediately stored 
at −80°C. When available, ileal biopsies of patients under-
going colonoscopy as part of their routine clinical man-
agement were collected. All patients signed an informed 
consent to participate in the study and the Ethics Committee 
of Hospital General Universitario de Alicante approved the 
study protocol.
2.2 | Quantification of endocrine disruptors 
in serum samples of CD patients
EDCs bisphenol- A (BPA), ethylparaben (EtPB), methylpara-
ben (MePB), propylparaben (PrPB), butylparaben (BuPB), and 
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benzophenones (BzP- 1 and - 3) levels were quantified in serum 
samples using optimized techniques,24,25 and analyzed by dis-
persive liquid– liquid micro- extraction (DLLME) and ultra- 
high performance liquid chromatography with tandem mass 
spectrometry detection (UHPLC- MS/MS). Collecting, storing, 
and processing of serum biospecimens were performed under 
controlled conditions, avoiding potential external contamina-
tion from collection containers, equipment or labware.
2.3 | Estrogen receptors measurements in 
PBMCs from CD patients
RNA isolation and gene expression analysis for estrogen recep-
tor (ER)- α, ER- β and G Protein coupled Estrogen Receptor 1 
(GPER) were done using previously reported methodology.26 
Primer pairs are described in Supplementary Table 1.
2.4 | Microbial products in serum 
samples of CD patients
Bacterial DNA was detected by 16SrRNA gene amplification 
by polymerase chain reaction as previously described.27 Patients 
above the 10pg detection limit were considered as bacterial 
DNA positive. Serum endotoxin was measured by handling a 
chromogenic limulus amoebocyte lysate test (BioWhittaker, 
Nottingham, UK) following manufacturer’s instructions and as 
described elsewhere.28 Short- chain fatty acids (SCFAs) were 
measured by gas chromatography– mass spectrometry (GC- 
MS) on plasma samples (200 µL). Samples processing and 
analysis were performed following methodology previously 
reported and optimized by García- Villalba et al.29
2.5 | Tryptophan and GPER quantification 
in serum of CD patients
Serum levels of tryptophan and GPER were measured by 
handling a fluorometric Tryptophan assay kit (Abcam, 
Cambridge, UK) and the human GPER ELISA Kit (Cloud- 
Clone Corp., Houston, TX), respectively, following manu-
facturer's instructions. Samples were run in triplicate and 
read at 440 nm for tryptophan and at 450 nm for GPER for 
quantification.
2.6 | Tight- junctions gene expression levels
RNA from available ileal samples conserved in RNAlater 
was isolated and used to analyze gene expression of zona 
occludens (ZO)- 1, claudin-1 and occludin. Primer pairs are 
described in Supplementary Table 1.
2.7 | CD associated 
polymorphisms genotyping
Single- nucleotide polymorphisms for NOD2/CARD15 (SNP- 
8, R702W, rs2066844; SNP- 12, G908R, rs2066845; SNP- 13, 
L1007finsC, rs2066847) and the ATG16L1 variation rs2241880 
were genotyped as previously described.7 A variant genotype 
was considered either present in homozygosis or heterozygosis.
2.8 | Statistical analysis
The statistical analysis of results was run on SPSS 19.0 soft-
ware (Chicago, IL). Qualitative variables are described as 
frequencies or percentages. Quantitative variables following 
normal distribution were described as mean and standard de-
viation. The differences between groups in the experimental 
qualitative and quantitative variables were studied by means 
of the chi- square test and either the Student's t test or the 
Mann- Whitney U test for quantitative variables. Bonferroni 
correction was used for multiple comparisons. The association 
between continuous variables was explored through correla-
tion analyses, and multivariate linear regression analyses were 
carried out to explain the variability and possible associations 
of variables. Significance was considered for P < .05 values.
3 |  RESULTS
3.1 | Clinical and analytical characteristics 
of CD patients
A series of 200 CD patients (140 patients in remis-
sion, 60 patients with active disease) were included in the 
study. Mean CDAI scores were 94 ± 27 versus 181 ± 38, 
P = .001; Fecal calprotectin levels were 95.8 ± 56.4 versus 
840.3 ± 580.6, P = .001; and PCR values were 0.37 ± 0.60 
versus 0.84 ± 0.90, P = .09, respectively. No differences in 
the Montreal classifications were present between patients in 
remission and active patients. Table 1 resumes clinical and 
analytical characteristics of both groups of CD patients.
3.2 | Serum endocrine disruptors in 
CD patients
Serum levels of selected endocrine disruptors are shown in 
Table  2. BPA levels showed the highest concentrations in 
blood among studied EDCs and, despite variability, its con-
centration was significantly elevated in active patients com-
pared to patients in remission (Figure 1A). No correlations 
were found between serum BPA levels, calprotectin and CRP 
in patients in remission. However, a significant correlation 
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was found between fecal calprotectin and serum BPA lev-
els among active CD patients (Figure 1B). Gene expression 
levels of ER- α (Figure 1C) and ER- β (Figure 1D) in PBMCs 
were not significantly different between patients in remis-
sion and active patients. GPER mRNA expression levels 
were significantly increased in patients with active disease 
(Figure 1E). GPER protein levels correlated positively with 
BPA levels (r = 0.708; P = .001) (Figure 1F), Phenotypically, 
serum BPA levels were significantly increased in patients 
with colonic versus ileal disease (Figure 1G). No differences 
in serum BPA levels were observed according to the presence 
of perianal disease or the use of biologics, either in regular or 
intensified regime. No correlations were found for the rest 
of EDCs investigated on CD disease activity or phenotype. 
No significant differences by gender were present in our co-
hort for EDCs and estrogen receptor levels (Supplementary 
Patients in remission 
(n = 140)
Patients with active 
disease (n = 60)
Gender, male (%) 67 (47.8%) 30 (50%)
Age (years) 40 ± 14 40 ± 15
Smoking habit, yes (%) 47 (33.5%) 25 (41.6%)
CDAI 72.7 ± 38.5 230 ± 83.7*
Disease duration (months) 110 ± 100 85 ± 100
Previous surgery, yes (%) 42 (30%) 16 (26.6%)
Montreal classification, n (%)
Age of onset
A1 10 (7.1%) 4 (6.7%)
A2 103 (73.6%) 43 (71.6%)
A3 27 (19.3%) 13 (21.7%)
Location
Ileal 69 (49.3%) 34 (56.7%)
Ileocolonic 29 (20.7%) 9 (15%)
Colonic 42 (30%) 17 (28.3%)
Behavior
1 73 (52.1%) 29 (48.4%)
1p 16 (11.4%) 8 (13.3%)
2 19 (13.6%) 11 (18.3%)
2p 5 (3.6%) – 
3 21 (15%) 8 (13.3%)
3p 6 (4.3%) 4 (6.7%)
Perianal activity, yes (%) 27 (19.3%) 11 (18.3%)
Extraintestinal manifestations, yes (%) 27 (19.3%) 7 (11.7%)
Therapy, n (%)
No treatment 38 (27.2%) 15 (25%)
IS 57 (40.7%) 29 (48.3%)
Biologics 29 (20.7%) 11 (18.4%)
IS + Biologics 16 (11.4%) 5 (8.3%)
Use of steroids, yes (%) 9 (6.4%) 26 (43.3%)*
Total leukocytes (mm3) 6946 ± 2520 7736 ± 2670
Hemoglobin (g/dL) 13.8 ± 1.4 13.1 ± 1.5
Albumin (g/dL) 4.1 ± 0.4 3.6 ± 0.6
CRP (mg/dL) 0.4 ± 0.6 1.7 ± 3.0*
Fecal calprotectin (µg/g) 95.6 ± 56.2 795.8 ± 545.5*
Abbreviation: CRP, C- reactive protein.
*P < .01 compared to patients in remission.
T A B L E  1  Patients’ clinical and 
analytical characteristics
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Table 3). No significant differences among women distrib-
uted by the use of hormonal contraceptives or by being on 
menopause were present in our cohort of patients for estrogen 
receptor gene expression levels (Supplementary Table 4).
3.3 | Serum BPA levels and microbiota 
dysbiotic products in CD patients
We evaluated the interaction between BPA levels with sev-
eral surrogated markers of microbiota dysbiosis in CD pa-
tients. First, thirty- eight patients among those in remission 
(27.1%) and 32 active patients (53.3%) showed detectable 
bacterial DNA in blood. Serum BPA levels were significantly 
higher in patients with bacterial DNA translocation, both in 
remission and active groups (Figure 2A), and a positive cor-
relation between fecal calprotectin and BPA levels in the 
overall series of patients with bacterial DNA, irrespective of 
disease activity (Figure 2B). ZO- 1 and claudin 1 mRNA lev-
els in available ileal samples from patients with versus with-
out bacterial DNA translocation were significantly decreased 
regardless disease activity (Figure 2C- E). No significant dif-
ferences were found in ER- α and ER- β gene expression lev-
els between remission and disease activity in available ileal 
samples. However, GPER transcriptional levels were signifi-
cantly increased in ileal samples from active patients com-
pared to those in remission (Supplementary Table 5).
To determine whether an active disease- independent as-
sociation between bacterial DNA translocation and serum 
BPA levels was present, a linear regression analysis was run 
including both variables. Disease activity (OR 4.473 [1.472- 
7.474], P = .004) and bacterial DNA translocation (OR 6.346 
[3.664- 9.028], P = .001) remained as independent variables 
associated with serum BPA levels.
Second, serum endotoxin levels were significantly higher 
in the overall series of active patients versus patients in re-
mission (2.6 ± 1.1 vs 1.1 ± 0.8 UE/mL, P = .001). Serum 
endotoxin levels were significantly higher in patients with 
bacterial DNA in blood compared to those without transloca-
tion of bacterial genomic fragments, even among patients in 
remission (Figure 3A). Serum BPA levels significantly cor-
related with endotoxin levels, irrespective of disease activity 
(r = 0.417; P = .003) (Figure 3B).
Third, serum levels of SCFAs were measured in all in-
cluded patients (Table 3). As shown, although serum levels 
of all detected SCFAs were higher among patients in remis-
sion compared to active patients, no statistically significant 
difference was reached for any SCFA. Valeric acid was not 
detected in the serum of our series of CD patients. However, 
butyric, isobutyric, and isovaleric acids were significantly 
decreased among patients with bacterial DNA transloca-
tion, irrespective of disease activity (Table 3), Serum butyric 
acid levels were significantly lower in patients with bacte-
rial DNA in blood compared to those without bacterial DNA 
translocation, even among patients in remission (Figure 3C). 
An inverse relationship was present between serum butyric 
acid and BPA levels (r = −0.491; P = .001) (Figure 3D).
Finally, tryptophan levels were measured in the serum of CD 
patients. Although patients with active disease showed lower 
levels than patients in remission, only patients without evidence 
of bacterial antigen translocation in blood presented signifi-
cantly lower levels of tryptophan compared to patients without 
bacterial DNA in blood (Figure 3E). Tryptophan levels showed 
an inverse significant correlation with BPA levels (r = −0.611; 
P = .001) (Figure 3F) in the overall series of patients.
3.4 | Serum BPA levels are not associated 
with variant NOD2 and ATG16L1 genotypes in 
CD patients
NOD2 and ATG16L1 were genotyped in all patients. One 
hundred and nineteen patients (59.5%) presented any of 
the studied NOD2 variant genotypes, whereas 83 patients 
(41.5%) showed an ATG16L1 variant genotype. The com-
bination of both variant genotypes was present in 55 CD 
Concentration (µM)
Patients in remission 
(n = 140)









Abbreviations: BPA, bisphenol A; BuPB, butylparaben; BzP- 1, benzophenone- 1; BzP- 3, benzophenone- 3; 
EtPB, ethylparaben; MePB, methylparaben; PrPB, propylparaben.
*P < .01 compared to patients in remission.
T A B L E  2  Serum levels of evaluated 
endocrine disrupting chemicals.
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F I G U R E  1  A, BPA levels in serum of CD patients distributed by disease activity. B, Correlation between serum BPA and fecal calprotectin 
in CD patients distributed by disease activity. C- E, Relative gene expression levels of ER- α (C), ER- β (D) and GPER (E) in PBMCs of CD patients 
distributed by disease activity. F, Correlation between serum BPA and GPER in CD patients distributed by disease activity. G, BPA levels in serum 
of CD patients distributed by disease location. BPA, bisphenol A; ER, estrogen receptor; GPER, G protein- coupled estrogen receptor
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patients (27.3%). No differences in serum BPA levels were 
present between CD patients according to this genotyping 
distribution (Supplementary Table 2).
3.5 | Serum BPA levels influence the 
systemic inflammatory response in CD patients
Table 4 resumes serum cytokine levels in our series of CD 
patients. Pro- inflammatory effector cytokines IFN- g and IL- 
17A, and their regulatory cytokines IL- 12, IL- 6 and IL- 23 
were increased in active patients, although differences didn’t 
reach statistical significance. However, the presence of bacte-
rial DNA in blood significantly increased IL- 23 and IL- 17A, 
irrespective of disease activity. Serum BPA levels showed a 
weak correlation with IL- 12 (r = 0.353; P = .005) and IFNg 
(r = 0.315; P =  .007). A stronger positive correlation was 
present between serum BPA and IL- 23 (r = 0.807; P = .001) 
(Figure 4A) and IL- 17A (r = 0.743; P = .001) (Figure 4B). 
Serum LPS, butyric acid and tryptophan levels were also 
associated with IL- 23 and IL- 17A levels in our series of CD 
patients. Treatments were not associated with significant 
differences in any cytokine levels. Among all variables, the 
multivariate analysis revealed an independent significant 
contribution of BPA and bacterial DNA to serum levels of 
IL- 23 and IL- 17A (Table 5).
4 |  DISCUSSION
The present proof- of- concept study shows the multifacto-
rial interaction of BPA on Crohn's disease. Serum BPA is 
associated with activity and phenotype of disease, it corre-
lates with BT markers and microbiota secretory products, 
and it independently influences patients’ systemic inflam-
matory response. These results provide evidence of an 
endocrine- disrupting factor playing an actual pathogenic 
role on CD.
Identifying the causes driving CD is a complex task. 
While a consensus exists regarding the implication of genetic, 
F I G U R E  2  A, BPA levels in serum of CD patients sorted by the evidence of bacterial DNA translocation. B, Correlation between serum BPA 
and fecal calprotectin in CD patients distributed by the presence of bacterial DNA translocation. C- E, Relative gene expression levels of ZO- 1 (C), 
claudin 1 (D) and occludin (E) in available ileal samples of CD patients distributed by the presence of bacterial DNA translocation. BPA, bisphenol 
A; ZO- 1, zona occludens 1
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epithelial, immune, microbial and environmental factors, 
the relationships established between some of these factors 
remain partially unraveled. Although data analyzed from 
several GWAS identified 30 CD- specific loci, along with 
additional 110 loci shared with ulcerative colitis,30 genetic 
background seems to only explain partially the susceptibility 
to the disease.31 The relevance of a fine- tuned gut immunity 
to achieve homeostasis reveals the central role of immune 
alterations in developing local inflammation that may lead 
to systemic dissemination.32,33 In intimate relation with this, 
microbiota eubiosis is lost during CD and this fact centers 
microbial community and their products in the onset and 
F I G U R E  3  A, LPS levels in serum of CD patients sorted by disease activity and the evidence of bacterial DNA translocation. B, Correlation 
between serum BPA and LPS in CD patients distributed by the presence of bacterial DNA translocation. C, Butyric acid levels in serum of CD 
patients distributed by disease activity and the presence of bacterial DNA translocation. D, Correlation between serum BPA and butyric acid in CD 
patients sorted by the evidence of bacterial DNA translocation. E, Serum tryptophan levels in serum of CD patients distributed by disease activity 
and the presence of bacterial DNA translocation. F, Correlation between serum BPA and tryptophan in CD patients sorted by the presence of 
bacterial DNA translocation. BPA, bisphenol A; LPS, lipopolysaccharide
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progression of disease.34- 36 While the interaction between 
all these factors have been intensively studied, the role for 
certain environmental aspects in this multifactorial disease 
is yet to be placed.22,37 Studies focused in causative environ-
mental factors are challenging and have shown conflicting 
data.38 However, the relevance of endocrine and metabolic 
factors is demonstrated by the rapid growth of IBD incidence 
in newly developing countries, probably as a consequence of 
an increasing westernized lifestyle.39 Moreover, studies show 
that disease incidence in migrants is more similar to that in 
their adopted countries rather than in their country of origin, 
reflecting the importance of the environmental risk factors 
such as lifestyle, pollution or diet.40- 42
EDCs are environmental pollutants that have shown to 
affect chronic metabolic diseases,11,12 and to interact with 
gut microbiota favoring dysbiosis.19 Among different non- 
persistent EDCs evaluated, our results show that BPA is sig-
nificantly increased in serum of patients with active disease 
versus patients in remission. Regarding disease phenotype, 
serum BPA levels were higher in colonic versus ileal disease 
forms. Experimental studies have shown that BPA worsens 
disease activity during DSS- induced colitis, exacerbating in-
testinal inflammation,18 and a study evaluating urinary phe-
nolic compounds observed an association between increased 
4- tert- octylphenol levels and ulcerative colitis in a small sub-










Acetic acid (µM) 592.8 ± 674.4 597.4 ± 382.4 588.9 ± 724.6 603.8 ± 320.6
Propionic acid (µM) 69.6 ± 66.7 66.3 ± 22.5 70.4 ± 71.8 65.9 ± 19.2
Butyric acid (µM) 146.3 ± 58.2 140.6 ± 69.5 160.4 ± 63.8 114.3 ± 39.7*
Isobutyric acid (µM) 104.6 ± 43.2 93.6 ± 23.1 106.5 ± 46.2 95.0 ± 24.9*
Isovaleric acid (µM) 251.3 ± 111.1 227.7 ± 71.1 257.3 ± 114.5 227.7 ± 80.3*
*P = .001 compared to patients without bactDNA.










IL- 12 (pg/mL) 38.6 ± 17.2 42.5 ± 16.9 37.7 ± 16.2 43.1 ± 18.5
IFNg (pg/mL) 21.1 ± 10.9 26.1.3 ± 11.5 22.1 ± 10.2 27.7 ± 12.4
IL- 6 (pg/mL) 28.9 ± 16.3 27.7 ± 13.5 28.2 ± 16.3 29.5 ± 14.5
IL- 23 (pg/mL) 12.6 ± 10.4 16.5 ± 8.9 11.3 ± 6.3 18.1 ± 9.1*
IL- 17A (pg/mL) 26.6 ± 11.6 32.0 ± 16.6 23.9 ± 10.8 33.3 ± 15.2*
*P = .01 compared to patients without bactDNA.
T A B L E  4  Serum levels of cytokines
F I G U R E  4  A, Correlation between serum BPA and IL- 23 levels in CD patients sorted by the presence of bacterial DNA translocation. B, 
Correlation between serum BPA and IL- 17A levels in CD patients sorted by the detection of bacterial DNA translocation. BPA, bisphenol A; IL, 
interleukin
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serve as signal transducers for xenoestrogens EDCs.44 ERs 
have been implicated in CD activity. While lower levels of 
ER- β have been described in CD patients’ peripheral T cells, 
a higher expression of ER- α has been reported in this same 
population.45 In fact, the ratio ER- β/ER- α has been proposed 
as a tool for non- invasively monitoring CD activity.46 While 
we observe no significant differences in either ER- β or ER- α, 
a significant increase in GPER gene and protein expression 
levels can be observed in PBMCs, as well as in available ileal 
samples, from active CD patients. In line with this, Jacenik 
et al found GPER overexpression in intestinal mucosa sam-
ples from male CD patients and, by handling a murine model 
of CD, they showed that lower GPER expression is related 
with reduced colonic inflammation.47 Also, human mature 
adipocytes obtained from subcutaneous mammary adipose 
tissue and exposed to BPA increased GPER levels more 
than two- fold.48 Although we don't find differences in ERs 
transcriptional levels among women according to the use of 
hormonal contraceptives or menopause, this effect cannot be 
completely discarded, as the number of patients in those sub-
groups is short in our cohort.
Different experimental studies have also presented ev-
idence of microbiota modification in response to BPA ex-
posure. We were interested in evaluating this association in 
CD, as a gut microbiota dysbiotic state is present in these 
patients,34,36 contributing to inflammatory exacerbation.2,49 
Different surrogated markers of dysbiosis such as transloca-
tion of bacterial DNA, increased serum endotoxin levels or a 
reduced concentration of SCFAs in blood were studied in CD 
patients. Bacterial DNA translocation and endotoxin levels in 
blood were increased in active CD patients and a significant 
correlation could be established between both markers and 
BPA serum levels by linear regression analyses. These results 
support a disease activity- independent association between 
BPA and circulating bacterial products in the blood of CD 
patients. Accordingly, exposure of C57BL/6 mice to dietary 
BPA has been reported to reduce gut microbiota diversity 
and to increase Proteobacteria,20 common signatures of mi-
crobiota changes present in chronic inflammatory disorders. 
Additionally, BPA has been implicated in inducing hepatic 
steatosis in CD- 1 mice after promoting microbiota dysbio-
sis and gut- liver axis activation.50 These exposed mice show 
increased serum LPS, as shown by us in CD patients, and a 
disrupted gut barrier integrity, a hallmark in the pathophysi-
ology of CD.2,49
Further evidence on BPA interaction with bacterial- 
derived metabolites in CD patients is supported by the re-
duction observed in serum SCFAs, particularly butyric acid, 
and its significant inverse correlation with BPA. SCFAs are 
important modulators of gut homeostasis and their decrease 
is associated with a reduction in SCFA- producing bacterial 
clusters such as Clostridia, which are decreased in chronic 
inflammatory bowel and liver diseases.34,36,51,52 It is plausi-
ble that BPA contribution to the dysbiotic state may be influ-
encing SCFAs serum levels in CD patients. In fact, an inverse 
significant correlation is observed between BPA and butyric 
acid levels in these patients. Also, a significant reduction in 
Tryptophan levels, which have been related to disease activity 
in CD,53 is observed among patients with evaluated markers 
of dysbiosis in our series of patients. Actually, the reduction 
in Tryptophan and metabolites derived from aromatic ami-
noacids (MDAs) has been reported in feces of BPA- treated 
mice.18 Also, as microbiota content is more abundant in 
colon versus ileal segments, changes in microbiota compo-
sition, and their metabolite interaction with other inflamma-
tory triggers becomes especially relevant in this tissue. This 
may partially explain the association observed between BPA 
and colonic disease in our cohort of CD patients.
In addition to the close interaction observed between 
BPA serum levels and gut microbiota dysbiotic circulating 
products, this EDC pollutant seems to independently relate 
to systemic pro- inflammatory cytokine levels in CD patients 
(Figure 4). In line with these results, the ability of BPA to 
induce an inflammatory response has been reported previ-
ously in several studies. The amount of IL- 12, among other 
cytokines, is increased in colonic samples from DSS- mice 
treated with BPA.18 Serum TNF- α, IL- 6 and IL- 18 levels 
were significantly increased in BPA- fed CD- 1 mice com-
pared to controls.50 Studies in humans have also found posi-
tive correlations between BPA exposure and increased serum 
proinflammatory cytokines such as TNF- α or IL- 6.54,55 Of 
interest, we here show a direct relationship with IL- 23 and 
IL- 17, the cytokines driving stabilization and expansion 
and the effector Th17 response,56 mainly responsible for the 
inflammatory response in CD.57,58 Since diet is one of the 
major sources of exposure to BPA,59 and considering the 
lack of association found between BPA levels and distinct 
T A B L E  5  Multivariate analysis on serum cytokine levels
β IC 95% P
IL- 23
Disease activity (yes) 0.064 −2.072 to 2.201 .953
Bacterial DNA (yes) 3.503 1.047 to 5.959 .005
LPS −0.959 −2.424 to 0.506 .198
BPA 1.685 1.602 to 1.769 .001
Butyric acid −0.002 −0.014 to 0.010 .722
IL- 17A
Disease activity (yes) −0.885 −4.540 to 2.770 .633
Bacterial DNA (yes) 1.813 1.388 to 3.015 .006
LPS −0.348 −2.854 to 2.159 .785
BPA 1.146 1.003 to 1.289 .001
Butyric acid 0.001 −0.020 to 0.020 .969
Bold value is used to remark statistically significant variables.
Abbreviations: BPA, bisphenol A; IL, interleukin; LPS, lipopolysaccharide.
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CD- related genes variant genotypes, these results strengthen 
the benefits of a healthy lifestyle in helping maintain the im-
mune homeostasis.
We acknowledge the limitations derived from this study. 
In first place, other EDCs such phthalates, perfluorinated 
compounds, and polycyclic aromatic hydrocarbons have 
not been evaluated and might play as well a role in disease 
activity and patients’ inflammatory outlook. Also, BPA ex-
posure was assessed in a single serum sample, which may 
lead to exposure misclassification due to its non- persistent 
nature and short- term viability.60 However, this might result 
in attenuation bias, rather than an overestimation of effects. 
Nevertheless, we consider that presented data constitute a 
proof- of- concept showing BPA interactions with known 
CD inflammatory triggers, mainly derived from dysbiotic 
gut microbiota in a large real- life cohort of CD patients. A 
proposed multifactorial interacting scheme is presented in 
Figure 5.
In summary, results presented herein provide evidence on 
endocrine perturbation influencing disease activity through 
the BPA association with increased bacterial DNA transloca-
tion and serum endotoxin levels, and with decreased SCFAs 
and tryptophan levels, affecting the systemic inflammatory 
response that allows a sustained Th17 activation in CD 
patients. Further studies are needed to characterize the func-
tional interaction of other EDCs with gut microbiota- derived 
metabolites in CD.
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